Liquidia Corporation (LQDA)
| Market Cap | 5.06B +327.6% |
| Revenue (ttm) | 288.07M +1,936.7% |
| Net Income | 22.31M |
| EPS | 0.24 |
| Shares Out | 88.93M |
| PE Ratio | 233.20 |
| Forward PE | 13.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,143,181 |
| Open | 57.74 |
| Previous Close | 59.30 |
| Day's Range | 56.08 - 58.70 |
| 52-Week Range | 11.85 - 59.75 |
| Beta | 0.42 |
| Analysts | Strong Buy |
| Price Target | 45.36 (-20.32%) |
| Earnings Date | May 11, 2026 |
About LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L6... [Read more]
Financial Performance
In 2025, Liquidia's revenue was $158.32 million, an increase of 1031.18% compared to the previous year's $14.00 million. Losses were -$68.92 million, -46.28% less than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for LQDA stock is "Strong Buy." The 12-month stock price target is $45.36, which is a decrease of -20.32% from the latest price.
News
Liquidia Transcript: Bank of America Global Healthcare Conference 2026
YUTREPIA's launch has exceeded expectations, achieving rapid revenue growth, expanding market share, and maintaining strong financial discipline. The company is investing in clinical studies, sales force expansion, and manufacturing to capture a $3–5 billion market opportunity, with a $1 billion revenue target for 2027.
Liquidia price target raised to $67 from $55 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Liquidia (LQDA) to $67 from $55 and keeps a Buy rating on the shares. Liquidia delivered a strong quarter…
Liquidia price target raised to $62 from $51 at Wells Fargo
Wells Fargo raised the firm’s price target on Liquidia (LQDA) to $62 from $51 and keeps an Overweight rating on the shares. The firm says Yutrepia appears to be disrupting…
Liquidia price target raised to $60 from $57 at Jefferies
Jefferies analyst Amy Li raised the firm’s price target on Liquidia (LQDA) to $60 from $57 and keeps a Buy rating on the shares following “strong” Q1 results. The firm…
Liquidia Earnings Call Transcript: Q1 2026
YUTREPIA drove 44% sequential sales growth and tripled EBITDA in Q1 2026, achieving over $500M annualized run rate. Market share in inhaled prostacyclins neared 23%, with robust expansion in both PAH and PH-ILD segments. Management maintains confidence in reaching $1B revenue by 2027.
Liquidia reports Q1 EPS 52c, consensus 41c
Reports Q1 revenue $129.9M, consensus $119.4M. Cash and cash equivalents totaled $222.8M as of March 31, 2026, vs. $190.7M as of December 31, 2025. CEO Roger Jeffs said: “In its…
Liquidia Corporation Reports First Quarter 2026 Financial Results
YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026 More than 4,500 unique patient prescriptions and approximately 3,750 patients tr...
Liquidia Corporation to Participate in Upcoming Investor Conferences
MORRISVILLE, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challengin...
Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026
MORRISVILLE, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challengin...
Liquidia Transcript: 25th Annual Needham Virtual Healthcare Conference
YUTREPIA has rapidly gained market share with strong patient uptake, robust financial performance, and broad prescriber adoption. Expansion of the sales force, new clinical studies, and a focus on displacing oral therapies are expected to drive growth toward a $1 billion revenue target by 2027. Legal and competitive dynamics remain important watchpoints.
Liquidia price target raised to $51 from $44 at Wells Fargo
Wells Fargo analyst Tiago Fauth raised the firm’s price target on Liquidia to $51 from $44 and keeps an Overweight rating on the shares. The firm believes the pulmonary hypertension…
Liquidia Technologies put volume heavy and directionally bearish
Bearish flow noted in Liquidia (LQDA) Technologies with 2,137 puts trading, or 1.1x expected. Most active are Apr-26 30 puts and Mar-26 20 puts, with total volume in those strikes…
Liquidia price target raised to $19 from $16 at Oppenheimer
Oppenheimer raised the firm’s price target on Liquidia (LQDA) to $19 from $16 and keeps an Underperform rating on the shares. The firm gives credit to the Liquidia team for…
Liquidia price target raised to $55 from $50 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Liquidia (LQDA) to $55 from $50 and keeps a Buy rating on the shares. The company’s “impressive” Q4 earnings support the view…
Liquidia files automatic mixed securities shelf
16:41 EST Liquidia (LQDA) files automatic mixed securities shelf
Liquidia Earnings Call Transcript: Q4 2025
YUTREPIA achieved rapid adoption and profitability, driving 74% sequential sales growth in Q4 2025 and expanding market share to 17%. Management projects continued momentum, robust cash flow, and targets $1 billion revenue by 2027, with ongoing clinical expansion.
Liquidia reports Q4 EPS 15c, consensus 33c
Reports Q4 revenue $92.02M, consensus $87.49M. Roger Jeffs, Liquidia’s (LQDA) CEO, said: “As we close 2025, we are encouraged by how quickly YUTREPIA has taken hold in clinical practice, placing…
Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
MORRISVILLE, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challeng...
Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026
MORRISVILLE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseas...
Liquidia reaction on United Therapeutics’ TreSMI reveal ‘overdone,’ says Needham
Liquidia (LQDA) shares fell 10% following United Therapeutics’ (UTHR) surprise unveiling of TreSMI, a next-gen inhaled treprostinil aimed at reducing cough, despite no disclosed clinical data and plan...
Liquidia Technologies call volume above normal and directionally bullish
Bullish option flow detected in Liquidia (LQDA) Technologies with 55,048 calls trading, 9x expected, and implied vol increasing over 18 points to 161.19%. Jan-26 35 calls and 1/30 weekly 36…
Liquidia Transcript: 44th Annual J.P. Morgan Healthcare Conference
Profitability was achieved in the first quarter of launch, with rapid market share gains and strong cash flow. Yutrepia and L606 are driving growth through new indications and clinical studies, with plans to double manufacturing capacity and expand globally.
Liquidia price target raised to $55 from $45 at Jefferies
Jefferies analyst Amy Li raised the firm’s price target on Liquidia (LQDA) to $55 from $45 and keeps a Buy rating on the shares after the company announced “strong” preliminary…
